eyenovia-logo 3

Investor Relations

Corporate Profile
Eyenovia is a late-stage biopharmaceutical company with three lead programs in glaucoma, mydriasis and dry eye with a transformative ophthalmic delivery platform. Using breakthrough piezo-print technology for high-precision micro-dosing and the first smart electronic mobile health compliance tracking platform for topical pharmaceuticals, Eyenovia is building a premier eye care company of the future. The company is advancing its two lead assets for glaucoma and mydriasis into Phase III clinical programs and preparing registration studies for a third OTC product for dry eye. Eyenovia is expected to complete all three development programs through registration by 2020. Eyenovia is building a portfolio of superior micro-therapeutics with its proprietary piezo-formulations of existing and new molecular entities.


 - 0.22 (4.01%)


Data provided by Nasdaq. Minimum 15 minutes delayed.

Recent News Releases
Eyenovia Reports Second Quarter 2018 Financial Results
Read More
Eyenovia’s EYN PG21 Trial Evaluating High-Precision Microdose of Latanoprost Demonstrates Robust Intraocular Pressure Lowering and Patient Usability
Read More
Eyenovia Announces Conference Call and Webcast for Second Quarter 2018 Financial Results
Read More
Upcoming Events
There are currently no events scheduled.

Transfer Agent
American Stock Transfer & Trust Company, LLC
6201 15th Avenue
Brooklyn, NY  11219
(718) 921-8124 (phone)
(718) 921-8386 (fax)
[email protected]

Contact us for more information

Contact us today to learn more about how our microdosing technology is poised to transform
the standard of care in ophthalmic therapeutic delivery.

New York    501 Fifth Avenue, Suite 1404 New York NY 10017     +1 (917) 289-1117

[email protected]